Table of Contents
PLAINSBORO, N.J. – Novo Nordisk has announced that the U.S. Food and Drug Administration has confirmed the resolution of the shortage of its prescription GLP-1 medications, Wegovy and Ozempic. The FDA states that the current supply of these semaglutide treatments, which are FDA-approved, now meets or exceeds both current and anticipated demand.
In response to rising demand, Novo Nordisk has intensified its manufacturing efforts, running production facilities 24/7 to guarantee uninterrupted shipments of all doses to wholesalers. The company has invested $6.5 billion this year alone to expand its U.S. manufacturing capacity.
"We are pleased the FDA has declared that the supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding nationwide demand," said Dave Moore, Executive Vice President of U.S. Operations and Global Business Development and President of Novo Nordisk Inc. "No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients."
After the FDA's determination, creating or marketing unauthorized compounded versions of semaglutide medications like Ozempic or Wegovy is against compounding laws, except in rare instances.
To enhance patient access, Novo Nordisk has launched the Find My Meds app, an AI-driven tool aimed at helping users find available doses of Wegovy at retail pharmacies. This initiative seeks to assist individuals in locating their prescriptions more effectively, ensuring continuous care and better health outcomes.
For more information, visit Novo Nordisk’s website.
